A Study to Describe the Switching From a First- or Second-line Disease Modifying Therapy (DMT) to Ozanimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
NCT05658601 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 104
Last updated 2025-10-01
Summary
The purpose of this study is to describe the reasons, therapy, and/or disease for changing first or second line Disease Modifying Therapy (DMT) to ozanimod in participants with Relapsing Remitting Multiple Sclerosis (RRMS).
Conditions
- Multiple Sclerosis, Relapsing-Remitting
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Bristol-Myers Squibb · Bristol-Myers Squibb
Eligibility
- Min Age
- 18 Years
- Max Age
- 55 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-07-14
- Primary Completion
- 2025-07-03
- Completion
- 2025-07-03
Countries
- Italy
Study Locations
More Related Trials
-
Participants Preferences to Disease Modifying Agents in Relapsing Remitting Multiple Sclerosis Condition
NCT02598167 ·Status: COMPLETED
-
A Cross-sectional Study to Assess the Effectiveness and Safety of Ofatumumab (Kesimpta®) in Patients With Relapsing Multiple Sclerosis in the Spanish Clinical Practice
NCT06251986 ·Status: COMPLETED
-
A Study to Assess the Effectiveness and Safety of Ozanimod in Chinese Adults With Relapsing Multiple Sclerosis
NCT06396039 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)
NCT02294058 ·Status: COMPLETED ·Phase: PHASE3
-
A Post-Authorization, Long-term Study of Ozanimod Real-world Safety
NCT05605782 ·Status: ACTIVE_NOT_RECRUITING
-
RRMS: Disease PROgression and Myeloid Profiling After Bone Marrow TRANSPLANTation and Second Line Therapies
NCT06267781 ·Status: RECRUITING
-
Observational Study of the Effect of Ozanimod on Fatigue in Multiple Sclerosis Patients
NCT05319093 ·Status: TERMINATED
-
The 'Wearing Off' Effect of DMT
NCT05627271 ·Status: COMPLETED
-
Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod
NCT06529406 ·Status: RECRUITING ·Phase: PHASE4
-
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
NCT04586010 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Disease Modifying Therapies Withdrawal in Inactive Secondary Progressive Multiple Sclerosis Patients Older Than 50 Years (STOP-I-SEP)
NCT03653273 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis
NCT02047734 ·Status: COMPLETED ·Phase: PHASE3
-
Pilot Study to Assess Disease Stability in a Natalizumab to Dimethyl Fumarate Crossover Design
NCT01945359 ·Status: COMPLETED
-
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
NCT05156281 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS)
NCT01405820 ·Status: COMPLETED ·Phase: PHASE2
-
ITAKOS - Italian Observation, Multicenter, Prospective Study of Ofatumumab in RRMS Patients
NCT06345157 ·Status: ACTIVE_NOT_RECRUITING
-
Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).
NCT02525874 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Safety of Long Term Treatment With Teriflunomide 14 mg Once Daily in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis in a Long-term Extension Period
NCT02587195 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Multiple Sclerosis and Their Infants
NCT06133049 ·Status: ACTIVE_NOT_RECRUITING
-
Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change
NCT01317004 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
NCT07299019 ·Status: RECRUITING ·Phase: PHASE3
-
Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients
NCT01628393 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Allogenic Adipose Tissue-derived Mesenchymal Stromal Cells for the Treatment of Primary Progressive Multiple Sclerosis
NCT06592703 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
NCT02637856 ·Status: COMPLETED ·Phase: PHASE3
-
Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis
NCT03996291 ·Status: COMPLETED ·Phase: PHASE2